Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention
Takahiro Masuda(Jichi Medical University), Volker Vallon(Unknown), Jan Czogalla(Universität Hamburg), Alexander Kuczkowski(VA San Diego Healthcare System), Miriam Scadeng(University of Auckland), Michael Rose(VA San Diego Healthcare System), Yiling Fu(VA San Diego Healthcare System), Akiko Eguchi(Mie University), Ariel E. Feldstein(Pediatrics and Genetics), Maria Gerasimova(VA San Diego Healthcare System)
American Journal of Physiology-Endocrinology and Metabolism
December 18, 2013
Cited by 16
Related Papers
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5
|Journal of Clinical Investigation|2003|432
Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5
|Journal of Clinical Investigation|2003|404
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Maintenance of Metabolic Homeostasis by Sestrin2 and Sestrin3
|Cell Metabolism|2012|290